SCHEMBL6503264

SCHEMBL6503264

O=C(Nc1ccc(N2CCN(CCc3ccccn3)CC2)cc1)C1=C(c2ccc(C(F)(F)F)cc2)CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 6/20 0.51
DRD2 P14416 6/20 0.51
TRPV1 Q8NER1 2/20 0.44
PHGDH O43175 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
KLF5 Q13887 1/20 0.44
KCNH2 Q12809 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
HIF1A Q16665 1/20 0.42
EPAS1 Q99814 1/20 0.42
MCHR1 Q99705 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501876 0.87 CA1 (0.42) HTR1ADRD2KCNH2CA1CA2
SCHEMBL6500009 0.87 PHGDH (0.49) HTR1ADRD2TRPV1PHGDHSMN1; SMN2
SCHEMBL6501892 0.86 TRPV1 (0.59) TRPV1PHGDHSMN1; SMN2NPC1MAPT
SCHEMBL6489158 0.84 SMO (0.46) TRPV1
SCHEMBL6487662 0.84 TRPV1 (0.49) TRPV1
SCHEMBL6487840 0.83 TRPV1 (0.48) TRPV1
SCHEMBL6500678 0.83 TRPV1 (0.48) TRPV1
SCHEMBL6500685 0.83 TRPV1 (0.48) TRPV1
SCHEMBL6490132 0.83 LCK (0.39) HTR1ADRD2SMN1; SMN2NPC1MAPT
SCHEMBL6490805 0.82 HIF1A (0.64) SMN1; SMN2MAPTKDM4EHIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HTR1A 993/4885DRD2 2927/4885TRPV1 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.